Description: The presenters describe the process payers and employers can use to evaluate emerging medical device technologies, recent or pending FDA submissions for prescription drugs and experimental treatments that impact patient care, resource utilization and health care expenditures. Learn the process of identifying and selecting impactful treatments (Horizon Scanning) and quantifying the financial cost of new technologies before they arrive in the market. These workflows can be leveraged by actuaries, healthcare economists, clinicians and pharmacists from a payer (Commercial and Medicare) and employer perspective for self-funded plans. Walk through sample models that illustrate how costs for emerging technologies and treatments can be modeled.

Description: The International Association of Insurance Supervisors (IAIS) continues its development of the Insurance Capital Standard (ICS) with the introduction of ICS 1.0 in summer 2017 and plans for ICS 2.0 in 2019. This session will provide updates on the development of the standards and summarize insights from Field Testing and ICS Consultations. This session will deliver an overview of the framework and provide industry and regulatory perspectives on potential implications and next steps.